
Opinion|Videos|February 7, 2025
Outcomes with Faricimab and Choosing Between the New Therapies
Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In clinical trials, faricimab showed noninferior vision outcomes compared to aflibercept 2 mg. What added benefit do you see by targeting Ang-2?
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
Port Delivery System Therapies in Retinal Vascular Diseases
5























